Kornimate/medical-research-clean huggingface dataset:
the effects of warm application in birth on birth pain, birth satisfaction and birth results

Conditions: Labor; Pregnancy; Active Phase

Summary: the use of non-pharmacological methods in labor pain is very important in order to improve the birth process, increase comfort and provide relaxation. the role of midwives, acting as patient advocate is to maintain comfort throughout the birth process. in order to do this, she should know very well the non-pharmacological methods to be applied to the pregnant woman and choose the most appropriate one. applying a warm shower, which is one of the non-pharmacological methods; the uterus increases perfusion, makes labor painless felt, increases the release of oxytocin, and decreases the release of stress hormones. in addition, while reducing the intervention rates, it improves birth and newborn outcomes and affects positively. purpose of the research; labor pain of warm shower application, labor to evaluate the effect on satisfaction and birth outcomes.


Eligibility criteria:
inclusion criteria: * between the ages of 18 and 35, * between 37 and 42 weeks of pregnancy, * planning a normal birth, * does not have a chronic health problem, * at least 20 minutes of non-stress test (nst) tracing is reactive, * those without premature rupture of membranes (emr) or those with prom not exceeding 6 hours from the opening time of the membranes, * speaking turkish and not having any communication barriers, * including pregnant women who voluntarily accepted to participate in the study will be. exclusion criteria: * the mother's refusal to be involved in the study * the use of analgesic methods during the birth process, * abnormal changes in fetal heartbeats, * unexpected complications (dizziness, fatigue) * pregnant women who decided to have an emergency cesarean section

Keywords: warm shower labor pain birth satisfaction
comparison of four intensive care scores in prediction of va-ecmo survival.

Conditions: Cardiogenic Shock; Extracorporeal Membrane Oxygenation Complication

Summary: va-ecmo is increasingly utilized in the setting of cardiogenic shock or cardiac arrest to restore hemodynamic stability and end organ function. va-ecmo serves as a short-term ventricular assist device that can be rapidly placed at the bedside in the emergency room, intensive care unit, cardiac catheterization suite, or operating room. a bridge to decision approach allows for the assessment of neurologic status, renal and hepatic function, and subsequent recovery of cardiac function. despite its life-saving potential, va-ecmo is fraught with complications including vascular complications from cannulation. in addition, neurologic injury, renal failure, liver failure, and sepsis are all well described sequelae of the post-cardiogenic shock or cardiac arrest va-ecmo patient. for these reasons, identifying early prognostic indicators and developing a score with regard to the outcome of this special patient population is of high interest. the proposed study aims to analyze 4 icu scores/survival prediction models \[apache-ii (acute physiology and chronic health evaluation ii), save (survival after va ecmo) , sofa (sequential organ failure assessment )and casus (cardiac surgery score)\] and evaluate their performance in predicting survival after va ecmo insertion. this will be a clinical retrospective study which will be conducted in the cardiothoracic intensive care unit (cticu) in the department of cardiothoracic surgery, heart hospital, doha. patients admitted to the cticu after institution of va ecmo in the period between 1st january 2015 to 31st october 2022 will be screened retrospectively. patients who stay for at least 12 hours in the cticu would be eligible for inclusion in the study. all charts of patients who were admitted to cticu after institution of va ecmo during the afore mentioned period will be included in the review. all the risk scores would be calculated separately for all the enrolled patients and then subjected to statistical analysis to determine predictive accuracy for survival.


Eligibility criteria:
* inclusion criteria * age more than18 years old. * patients undergoing institution of va ecmo * exclusion criteria * patients staying \< 12 hours in the icu
effect of periodontal treatment on salivary biomarkers

Conditions: Chronic Periodontitis

Summary: the investigators plan to recruit 40 healthy patients referred to the unit of periodontology, diagnosed with generalized moderate - severe chronic periodontitis. treatment will include 4 - 6 sessions of scaling + root planning, oral hygiene instructions and motivation. whole saliva will be collected at intake and 8 - 14 weeks post periodontal treatment. saliva will be analyzed for trans locator protein. study hypothesis: periodontal treatment has an affect on saliva components.


Eligibility criteria:
inclusion criteria: * healthy patients * moderate - sever chronic periodontitis exclusion criteria: * systemic disease * pregnancy * subjects under the age of 18
effect of a novel nutraceutical on weight loss and weight maintenance in obese subjects

Conditions: Obesity

Summary: the purpose of this 2-stage intervention study is to investigate the effect of a novel nutraceutical (containing tetrahydro iso-alpha acids derived from hops) on weight loss and weight loss maintenance in obese participants.


Eligibility criteria:
inclusion criteria: * bmi ≥ 30 and ≤ 47 exclusion criteria: * prohibited medications, supplements or herbal products 1. use of narcotics, oral or injectable corticosteroids, multivitamin/multimineral supplements, antioxidant supplements, vitamin d supplements, probiotics and omega-3 fatty acid supplements 30 days prior to screening and for the duration of the study. 2. use of prescription medications and/or nonprescription medications for acute medical conditions, semi-acute medical conditions, and weight loss. 3. change in prescription, otc, nutritional supplements and or medical foods within 30 days prior to the beginning of the study and for the duration of the study. * medical history and concurrent diseases 1. known allergy or hypersensitivity to study product or placebo. 2. clinically significant abnormalities in medical history of physical examination. 3. clinically relevant conditions expected to preclude achievement of exercise recommendation. 4. hepatic, renal, gastrointestinal, respiratory, cardiovascular, endocrinologic, neurologic, immunologic, or hematologic disease. 5. diabetes mellitus, irritable bowel syndrome, gastro-esophageal reflux disease, hiv, tb ,hepatitis b or c, malignancy, sleep apnea, insomnia (requiring use of sleeping medication more than once weekly), night eating syndrome, anorexia nervosa, bulimia, of non-specific eating disorder, and serious psychiatric illness. 6. smoking or use of nicotine containing products within 30 days prior to screening and for the duration of the study. 7. use of drugs of abuse (e.g. marijuana, cocaine, pcp, and methamphetamine) within 30 days prior to screening and for the duration of the study. * other criteria 1. initiation of a new or change of an existing exercise regiment within 30 days prior to screening. 2. initiation of a new or change of an existing food plan within 30 days prior to screening.
southern china registry for stroke on traditional chinese medicine

Conditions: Stroke; Cerebral Infarction; Transient Ischemic Attack; Cerebral Hemorrhage; Subarachnoid Hemorrhage

Summary: stroke is the first most common cause of death in china and one of the major causes of functional disability in the adult population.the burden of stoke is significantly increased in china in recent years. in order to investigate the prognosis of stroke, with diagnostic and treatment information of traditional chinese medicine (tcm), and assess the effectiveness and safety of tcm for stroke in southern china, the investigators will conduct this multicenter prospective registry study in southern china. this study will recruit 10,000 consecutive eligible patients with acute stroke from more than 50 hospitals. 24 months follow-up will be carried out on-site in hospitals and by telephone to track endpoint (including all-cause mortality, composite cerebrovascular and cardiovascular events at one and two year follow up, and neurological and functional assessments).


Eligibility criteria:
inclusion criteria: 1. ≥18 years. 2. patients within 14 days of onset of acute stroke (including acute cerebral infarction, transient ischemic attack, acute cerebral hemorrhage, acute subarachnoid hemorrhage). 3. the patient and/or guardian agree to participate in this study. exclusion criteria: 1. patients with silent cerebrovascular disease. 2. patients with non-cerebrovascular disease events.
study for treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck or skin

Conditions: Metastatic Head-and-neck Squamous-cell Carcinoma

Summary: this phase 2 study is designed to evaluate the safety and activity of th-4000, a hypoxia-activated prodrug in participants with recurrent or metastatic squamous cell carcinoma of the head and neck or skin.

an open label, multi-center phase 2 study in which the pharmacokinetics, safety, tolerability and efficacy of th-4000 will be assessed in participants with recurrent or metastatic squamous cell carcinoma of the head and neck or skin. hypoxia pet scans will be obtained in select centers to analyze potential predictors of tumor response.

Eligibility criteria:
inclusion criteria: * eastern cooperative oncology group (ecog) performance status 0-2 * confirmed squamous cell carcinoma (scc) of the head and neck (oropharynx, oral cavity, hypopharynx, or larynx) or skin * for patients with oropharyngeal cancer, p16 status is known or can be determined * measurable disease according to response evaluation criteria in solid tumors version 1.1 (recist 1.1) * acceptable laboratory results as indicated by protocol * acceptable cardiac function as indicated by protocol exclusion criteria: * received prior epidermal growth factor receptor (egfr) tyrosine kinase inhibitor (tki) therapy for recurrent or metastatic squamous cell carcinoma (e.g., oral egfr tkis such as erlotinib, gefitinib, or afatinib) * family history of long corrected qt interval (qtc) syndrome * receiving medication that prolongs qt interval ,with a risk of causing torsades de pointes (tdp), unless ecg meets inclusion criteria while on a stable dose of the medication * family history of long qtc syndrome * symptomatic central nervous system (cns) lesions, or cns lesions that require therapy * radiation therapy within 2 weeks prior to the first dose of study medication * major surgery within 4 weeks or minor surgery within 2 weeks prior to the first dose of study medication * concurrent active malignancy requiring systemic treatment * any other serious uncontrolled medical disorders or psychological conditions that may interfere with study conduct including but not limited to: clinically significant active infection * pregnant or breast-feeding

Keywords: squamous cell carcinoma the head and neck skin th-4000 hypoxia tarloxotinib
study of mk0663 in patients with chronic low back pain (0663-806)(completed)

Conditions: Chronic Low Back Pain

Summary: the purpose of this study is to evaluate the efficacy of mk0663 for the treatment of chronic low back pain and to investigate the overall safety and tolerability over four weeks of treatment.


Eligibility criteria:
inclusion criteria: * male and female patients 18 years of age or older, who have chronic low back pain after the discontinuation of their previous medication for their condition. * patients should have at least 3 months of low back pain.

Keywords: arcoxia
determination of target of adequate partial neuromuscular blockade for electrophysiologic monitoring during microvascular decompression surgery

Conditions: Hemifacial Spasm; Microvascular Decompression; Neuromuscular Blockade

Summary: there have been reports of monitoring lsr during mvd surgery helps predicting the clinical outcome of mvd. however, there have been no evidence of which degree of partial neuromuscular blockade should be performed during lsr monitoring under sevoflurane anesthesia. therefore, the investigators performed a randomized controlled trial to evaluate the effect of different degree of partial neuromuscular blockade on the lsr monitoring for mvd surgery.

hemifacial spasm develops by vascular compression of facial nerve at the root exit zone from brain stem. microvascular decompression (mvd) is known for its curative treatment. lateral spread response (lsr) is a kind of pathologic electromyographic (emg) wave form which develops when facial nerve is compressed by vessel. there have been reports of monitoring lsr during mvd surgery helps predicting the clinical outcome of mvd. as neuromuscular blockade during lsr monitoring decreases the amplitude of emg, partial neuromuscular blockade is usually maintained during general anesthesia for mvd. however, there have been no evidence of which degree of partial neuromuscular blockade should be performed during lsr monitoring under sevoflurane anesthesia. therefore, the investigators performed a randomized controlled trial to evaluate the effect of different degree of partial neuromuscular blockade on the lsr monitoring for mvd surgery.

Eligibility criteria:
inclusion criteria: * those who undergo microvascular decompression with sevoflurane anesthesia by diagnosis of hemifacial spasm in our institution exclusion criteria: * patients were excluded from the study if they had any of following: severe cardiopulmonary disorder with hemodynamic unstability (pulmonary hypertension, cardiomyopathy, mechanical ventilation, american society of anesthesiologists physical status iii or more), severe hepatic or renal disease. * those who can not undergo mep monitoring due to central or peripheral neuromuscular disease, e.g. cerebral palsy, myasthenia gravis, acute spinal injury, neurologic shock

Keywords: hemifacial spasm microvascular decompression neuromuscular blockade electromyography
volunteers adding life in dementia: valid

Conditions: Dementia; Alzheimer's Disease

Summary: older adults with alzheimer's disease and other forms of dementia frequently develop challenging neuropsychiatric symptoms (nps) as a result of their illness. non-pharmacological strategies to manage these symptoms such as music, exercise, and participating in pleasant social events have been demonstrated to be safe and effective strategies to reduce these behavioral symptoms. our project, volunteers adding life in dementia (valid), will design and implement a volunteer-led program to reduce behavioral symptoms and improve the quality of life of older adults with dementia who are residing in long-term care facilities.

the number of older adults with alzheimer's disease (ad) and related forms of dementia is increasing in canada and the majority of individuals with dementia develop neuropsychiatric symptoms (nps) such as agitation, psychosis, depression and anxiety at some time during their illness. nps are particularly problematic in long-term care (ltc) where approximately 60% of individuals have dementia, and 80% of individuals with dementia have nps at any time. adverse outcomes associated with nps include increased use of psychotropic medications, stress for families and nursing staff, increased costs of care, and decreased quality of life. a novel approach to implementing non-pharmacological interventions for ltc residents with nps is the use of volunteers. volunteer-led programs have been demonstrated to be an effective, inexpensive, and sustainable method of implementing psychosocial interventions for older adults in acute care. the objectives of our project are to: 1.) recruit and train approximately 40 volunteers in the valid program; 2.) conduct a cluster-randomized controlled trial of the valid program in 6 ltc facilities (3 intervention and 3 control ltc sites; 60 individuals with dementia in each of the experimental and control arms) to determine the effect of the valid program on symptoms of nps, patient quality of life, volunteer's experience, and ltc staff stress, 3.) determine key components of the valid program that served as facilitators and barriers to implementation.

Eligibility criteria:
inclusion criteria: * diagnosis of alzheimer's disease or related forms of dementia * significant symptoms of agitation as measured by a cohen-mansfield agitation inventory (cmai) total score of \>39 * resident in ltc facility for at least 30 days * presence of a caregiver or substitute decision maker willing to consent to treatment * no changes in psychotropic medications in the 2 weeks preceding enrolment in study exclusion criteria: * depressive symptoms presenting acute risk (i.e. suicidal ideation) * physically aggressive behavior posing safety risk to others * uncontrolled pain * currently receiving palliative care * medically unstable with life expectancy of \< 6 months * currently awaiting transfer to another ltc facility or hospital
idylla ifv-rsv panel clinical testing

Conditions: Respiratory Tract Infections; Influenza, Human; Respiratory Syncytial Virus Infections

Summary: this clinical study will collect fresh samples and perform laboratory testing on fresh and archived samples as described in the protocol.

the idylla console, instrument, and respiratory (ifv-rsv) panel cartridge constitute the idylla respiratory diagnostic system. the ifv-rsv panel is an in vitro pcr-based molecular diagnostic assay for the simultaneous qualitative detection of nucleic acids for influenza a (including h1, 2009 h1n1, h275y mutation of 2009 h1n1, h3), influenza b, and respiratory syncytial virus (rsv) (a and b) on nasal swab (ns) direct to cartridge or nasopharyngeal swabs (np) in viral transport media (vtm) in adults, adolescents, and children. this clinical study will collect data in support of regulatory submission and the indications for use of the ifv-rsv panel and the idylla diagnostic system. this protocol will demonstrate that the results of this assay, in conjunction with clinical information, may be used as an aid in the diagnosis of infection with influenza a, influenza b, and rsv in persons having both a high and low risk for respiratory viral infection. during this study, participating sites will collect fresh samples, conduct a reproducibility study and test the fresh and previously collected frozen samples from individuals presenting with signs/symptoms of influenza like illness (ili) and respiratory virus in accordance to the sample collection described in this protocol.

Eligibility criteria:
inclusion criteria: * male or female * all ages * subject, or legally authorized representative, has provided irb/ec approved written informed consent, privacy (e.g. hipaa) authorization when required and assent where applicable prior to any study-related procedure(s) being performed * patient presenting with ili and/or signs/symptoms of rsv infection as defined in this protocol * onset of ili and/or signs/symptoms of rsv infection was ≤ 5 days prior to subject screening (refer to the definitions for detailed descriptions of ili and signs/symptoms of rsv infection) * clinician's determination that illness is due to a viral infection * subject agrees to allow study specimens to be used for future studies exclusion criteria: * onset of influenza like illness (ili) and/or signs/symptoms of rsv infection was \> 5 days prior to subject screening (refer the definitions for detailed descriptions of ili and signs/symptoms of rsv infection) * subject received live intranasal attenuated influenza virus in last 3 weeks (e.g. flumist, fluenz) * subject received treatment with influenza directed antiviral (e.g. zanamivir, oseltamivir (tamiflu), amantadine, rimantadine) in the last 5 days * the subject was previously enrolled in this study * clinician's determination that illness is not due to a viral infection (e.g. allergies) * subject had a nasal wash within last 8 hours. this exclusion includes any extraction of nasal secretions by nasal suctioning with fluid * subject does not agree to allow study specimens to be used for future research studies
study of the determinants of emergency dialysis in reunion island

Conditions: Dialysis

Summary: among patients followed by nephrologists, the frequency of emergency dialysis starts' and their social and clinical determinants are not well known, especially in reunion island. in this context, we aim to study and understand the determinants of emergency dialysis initiation. for reunion island, the data remain very fragmented.


Eligibility criteria:
inclusion criteria: * adult patient ≥18 years * starting dialysis in a dialysis centre in réunion island * having expressed their non-opposition or emergency inclusion (non-opposition collected afterwards) exclusion criteria: * under legal protection (safeguard of justice, guardianship) * unable to answer questionnaires
deep tissue injury treatment with mist therapy versus standard care: reverse dti study

Conditions: Wound of Skin

Summary: the purpose of this study is to evaluate the effectiveness of mist therapy in conjunction with standard of care (soc) compared to soc alone in the prevention of deep tissue injury (dti) progression to advanced stage pressure ulcers.

enrolled subjects will be randomized to receive one of two treatment courses: a) mist therapy in conjunction with standard of care (mist + soc) (treatment group) or b) soc only (control group). a randomized subject will be required to undergo a baseline evaluation. the baseline evaluation. a digital photo will be taken of the wound. the subject will receive the assigned study treatment. each subject will receive soc wound care and off-loading daily throughout the study. subjects will be treated daily for 5 days and then every other day until discharged or up to 14 days post enrollment.

Eligibility criteria:
inclusion criteria: * male or female subject of any race 18-90 years old. * subject presents with an index dti. this is defined by the national pressure ulcer advisory panel (npuap) as a purple or maroon localized area of discolored intact skin or blood-filled blister due to damage of underlying soft tissue from pressure and/or shear. the area may be preceded by tissue that is painful, firm, mushy, boggy, warmer or cooler as compared to adjacent tissue. * subject's dti has been discovered ≤ 72 hours after causative event * causative event of dti is identified. * subject's index dti is located on torso or body extremities. * subject is currently admitted to the hospital. * subject is able to be maneuvered into a position that is acceptable for mist treatment. * subject's dti presents with no clinical signs of acute infection. * subject or subject's legally authorized representative understands the nature of the procedures and provides written informed consent prior to study enrollment. exclusion criteria: * subject's primary wound is a stage i, stage ii, stage iii or stage iv pressure ulcer. * subject's wound presents with a malignancy in the wound bed. * subject has a history of pressure ulcer / dti in same location. * subject's dti would require ultrasound near an electronic implant or prosthesis, e.g., near or over the heart, or over the thoracic area if the patient is using a cardiac pacemaker. * female subjects that are pregnant or refuse to utilize adequate contraceptive methods and are of childbearing age during the trial. * subject is terminally ill, defined as unable to survive beyond 14 days. * subject is known to be suffering from a disorder or other situation that the subject or investigator feels would interfere with compliance or other study requirements. * subject is currently enrolled or has been enrolled in the last 30 days in another device or drug trial.